Federated Hermes Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Federated Hermes Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 323,842 shares of the biopharmaceutical company’s stock after acquiring an additional 59,669 shares during the period. Federated Hermes Inc. owned about 0.25% of Alnylam Pharmaceuticals worth $105,602,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Evelyn Partners Investment Management LLP increased its stake in Alnylam Pharmaceuticals by 11.5% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 30 shares during the period. Bayforest Capital Ltd grew its position in shares of Alnylam Pharmaceuticals by 14.6% during the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares in the last quarter. MAI Capital Management grew its position in shares of Alnylam Pharmaceuticals by 9.2% during the second quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 41 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Alnylam Pharmaceuticals by 32.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,170 shares of the biopharmaceutical company’s stock worth $4,295,000 after purchasing an additional 45 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $458.12 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a market capitalization of $60.52 billion, a P/E ratio of 1,908.83 and a beta of 0.30. The company has a fifty day simple moving average of $456.78 and a two-hundred day simple moving average of $403.79. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Analyst Ratings Changes

A number of brokerages have issued reports on ALNY. Royal Bank Of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Truist Financial boosted their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Stifel Nicolaus increased their price objective on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a report on Monday, October 6th. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the transaction, the executive vice president owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 78,328 shares of company stock worth $35,705,793. 1.20% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.